^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1m
    A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Triplex (CMV-MVA vaccine)
    1m
    Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV (clinicaltrials.gov)
    P3, N=1557, Completed, Serum Institute of India Pvt. Ltd. | Recruiting --> Completed | Trial completion date: May 2026 --> Feb 2026
    Trial completion • Trial completion date
    1m
    Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer. (PubMed, Gynecol Oncol Rep)
    In the preclinical study, durable antitumor effect was achieved through combination treatment with Olvi-Vec and cisplatin in mouse model of PROC. Combination therapy of Olvi-Vec and platinum-doublet chemotherapy resulted in a clinically meaningful benefit in the VIRO-15 study, reversing the typical trend of deteriorating PFS, and with clinical reversal of platinum resistance. Olvi-Vec treatment can favorably modify the TME in OC and may explain the apparent reversal of platinum resistance following platinum rechallenge.Trial Registration:ClinicalTrials.gov Identifier: NCT02759588.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    cisplatin • olvimulogene nanivacirepvec (GL-ONC1)
    1m
    HVTN 317: Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. (clinicaltrials.gov)
    P1, N=96, Active, not recruiting, International AIDS Vaccine Initiative | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    Study of PlasmaCap IG in Adults and Children With PIDD (clinicaltrials.gov)
    P3, N=63, Completed, Evolve Biologics | Unknown status --> Completed
    Trial completion
    1m
    Self-assembled manganese-based nanoplatforms synergizing immunogenic cell death and STING activation for triple-negative breast cancer. (PubMed, Mater Today Bio)
    In this study, we developed a manganese-based nanoparticle, termed HLM315, via one-step self-assembly of alendronate-modified hyaluronic acid (HA-AL), the amphiphilic cationic peptide LTX-315, and Mn2+ under weakly alkaline conditions. Ultimately, HLM315 systematically reshaped the TME and potently inhibited the tumor growth in TNBC orthotopic mouse model. Overall, HLM315 establishes a coordinated antitumor immune cascade and offers a promising strategy to enhance immunotherapy efficacy in TNBC.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    Oncopore (ruxotemitide)
    1m
    RGL-270 + ICI in Advanced NSCLC (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Guangdong Association of Clinical Trials | Not yet recruiting --> Recruiting | Trial completion date: Jun 2028 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    1m
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (clinicaltrials.gov)
    P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    1m
    C4591059: Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | Trial completion date: Sep 2026 --> May 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    1m
    The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (clinicaltrials.gov)
    P3, N=4270, Completed, University of Chile | Recruiting --> Completed | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Jun 2025 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    1m
    A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=77, Suspended, University of California, Davis | Trial completion date: Jan 2030 --> Jan 2034 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2030
    Trial completion date • Trial suspension • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • MET mutation
    |
    Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)
    1m
    Trivalent Salmonella Conjugate Vaccine (TSCV) (clinicaltrials.gov)
    P2, N=800, Active, not recruiting, University of Maryland, Baltimore | Recruiting --> Active, not recruiting
    Enrollment closed